Actinium Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of pipeline plus net-cash floor. Net asset/cash floor = Total assets $40.16M minus total liabilities $9.86M (Q2 2026 10-Q) = $30.3M = $0.96/share on 31.44M shares. Lead asset Actimab-A: assumed peak annual sales of $250M, ~35% economic capture = $87.5M peak risk-unadjusted economics; 20% probability of success gives risk-adjusted peak cash flow of $17.5M/yr; valued as an 8-year annuity at a 12% discount rate = $87.0M at launch (year 4), discounted back 4 years = $50.8M today. Early-stage assets assigned a nominal $5M option value. Total = $30.3M + $50.8M + $5.0M = $86.1M / 31.44M shares = $2.74/share.

Reasoning: ATNM is a clinical-stage radiopharmaceutical biotech with lumpy, partnership-driven revenue rather than steady operating cash flow, so a standard DCF on trailing financials is not meaningful; an rNPV pipeline valuation anchored to a hard net-asset floor is the standard, defensible method for this business type.